Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150025/S018

PD-L1 IHC 28-8 pharmDx

Agilent Technologies, Inc. · Decision date Jul 1, 2026

FDA DECISIONP150025/S018

What did the FDA approve?

FDA records P150025/S018 as a supplement to PMA P150025, with the supplement type “Panel Track”. The recorded decision is approval, dated Jul 1, 2026.

FDA approval order statement

Approval for the PD-L1 IHC 28-8 pharmDx for expanding the indications to include use as an aid in identifying patients with esophageal squamous cell carcinoma (ESCC), and gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma for treatment with OPDIVO (nivolumab) or OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy).
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Pathology
Decision date
Jul 1, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P150025/S018
Regulatory pathway
PMA supplement
Product code
PLS
Decision code
APPR
Decision date
Jul 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry assay, antibody, programmed death-ligand 1.

Product code
PLS
FDA device class
3

For the original device and its historical approval scope, see PMA P150025. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150025 · Original PMA

    PD-L1 IHC 28-8 pharmDx

  2. P150025/S018 received

    Application receipt date recorded by FDA.

  3. P150025/S018 · FDA decision

    Panel Track

Timeline entries are records held by MedtechLedger for P150025. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150025

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA approvalOct 9, 2015FDA
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Other records with product code PLS

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA supplementSep 21, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Agilent Technologies, Inc.PMA supplementMar 19, 2026FDA
Agilent Technologies, Inc.PMA supplementFeb 11, 2026FDA
Agilent Technologies, Inc.PMA supplementFeb 10, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5301 Stevens Creek Blvd., Santa Clara, CA, 95051

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records